Leukemia Vaccine Galinpepimut-S Cut Death Risk 41% for AML Patients in Remission in Unreviewed Phase 3 Results
Company-reported Phase 3 results suggest galinpepimut-S improved survival for AML patients in remission who could not receive a stem cell transplant, though the findings remain unreviewed.
Medical Daily ·